Importantly, high post-treatment stromal CD8+ T-cell densities correlated with improved tumor regression, lower distant metastasis rates, and longer disease-free survival (DFS), suggesting that enhanced cytotoxic immune activation plays a key prognostic role across treatment strategies [40]. This evidence concerns the gene CD8A and neoplasm.